Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
BANK OF AMERICA CORP /DE/	DOUBLED	7	28	+300.0%	$108.00	2025-Q4
MORGAN STANLEY	NEAR_EXIT	401	1	-99.8%	$4.00	2025-Q4
MORGAN STANLEY	DOUBLED	1	401	+40000.0%	$2.6K	2025-Q3
UBS Group AG	DOUBLED	1	40	+3900.0%	$263.00	2025-Q3
BANK OF AMERICA CORP /DE/	NEAR_EXIT	4,089	7	-99.8%	$46.00	2025-Q3
BANK OF AMERICA CORP /DE/	NEW	—	4,089	—	$24.5K	2025-Q2

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 1 mixed, 1 neutral. Avg impact: 6.2/10.

BEARISH 8-K 8/10

Glucotrack received two Nasdaq deficiency notices: one for failing the $1.00 minimum bid price rule

May 15, 2026

NEUTRAL 8-K 5/10

Glucotrack reported Q1 2026 results with a net loss of $4.3M, narrower than the $6.8M loss in Q1 202

May 14, 2026

BEARISH 8-K 7/10

Glucotrack entered into an Exchange Agreement with an investor to partition a $988,000 promissory no

Apr 30, 2026

MIXED 8-K 5/10

Glucotrack reported full-year 2025 financial results showing a reduced net loss of $19.4 million com

Apr 21, 2026

BEARISH 8-K 6/10

Glucotrack, Inc. (GCTK) entered into an exchange agreement with an investor to convert a $600,000 pr

Apr 14, 2026

NEUTRAL 4/10

Glucotrack announced submission of an IDE application to the FDA to initiate a US clinical study for

May 7, 2026

MIXED 5/10

GlucoTrack, Inc. reported financial results for 2025, showing a reduced net loss of $19.4 million co

Mar 30, 2026

MIXED 6/10

Glucotrack, Inc. announced progress toward submitting an Investigational Device Exemption (IDE) appl

Mar 27, 2026

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Current FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 14, 2026

earnings

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. cl

May 7, 2026

fda

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform <pre>Submission supports advance

Apr 30, 2026

short_interest

FTD: GCTK — 797,810 shares ($0.7M) failed to deliver

Settlement: 20260430, Price: $0.92, FTD Value: $733,985.2, GLUCO TRACK INC

Mar 30, 2026

earnings

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in

Mar 30, 2026

short_interest

FTD: GCTK — 1,011,848 shares ($1.0M) failed to deliver

Settlement: 20260330, Price: $0.99, FTD Value: $1,001,729.52, GLUCO TRACK INC

Mar 27, 2026

fda

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM

Mar 27, 2026

short_volume

Short Volume: GCTK — 57.7% short (9.7M / 16.7M)

Short: 9,655,080 | Exempt: 86,403 | TRF Vol: 16,732,218 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)

Mar 10, 2026

other

Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit

RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company fo